K
Klaus Reither
Researcher at University of Basel
Publications - 119
Citations - 3846
Klaus Reither is an academic researcher from University of Basel. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 31, co-authored 103 publications receiving 3162 citations. Previous affiliations of Klaus Reither include Charité & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree,Norbert Heinrich,Rob E. Aarnoutse,Andreas H. Diacon,Rodney Dawson,Sunita Rehal,Gibson S. Kibiki,Gavin J. Churchyard,Gavin J. Churchyard,Ian Sanne,Nyanda E. Ntinginya,Lilian T. Minja,Robert D Hunt,Salome Charalambous,Madeleine Hanekom,Hadija H. Semvua,Stellah G. Mpagama,Christina Manyama,Bariki Mtafya,Klaus Reither,Klaus Reither,Robert S. Wallis,Amour Venter,Kim Narunsky,Anka Mekota,Sonja Henne,Angela Colbers,Georgette Plemper van Balen,Stephen H. Gillespie,Patrick P. J. Phillips,Michael Hoelscher +30 more
TL;DR: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens for the treatment of tuberculosis.
Journal ArticleDOI
Preferential infection and depletion of Mycobacterium tuberculosis–specific CD4 T cells after HIV-1 infection
Christof Geldmacher,Njabulo Ngwenyama,Alexandra Schuetz,Constantinos Petrovas,Klaus Reither,Klaus Reither,Edwin J. Heeregrave,Joseph P. Casazza,David R. Ambrozak,Mark K. Louder,William Ampofo,Georgios Pollakis,Brenna J. Hill,Erica Sanga,Elmar Saathoff,Leonard Maboko,Mario Roederer,William A. Paxton,Michael Hoelscher,Richard A. Koup +19 more
TL;DR: HIV-1 preferentially infects M. tuberculosis-specific CD4+ T cells due to their increased production of IL-2, which causes them to secrete polypeptide A in response to HIV-1 infection.
Journal ArticleDOI
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson,Andreas H. Diacon,Daniel Everitt,Christo van Niekerk,Peter R. Donald,Divan Aristo Burger,Divan Aristo Burger,Robert Schall,Robert Schall,Melvin Spigelman,Almari Conradie,Kathleen D. Eisenach,Amour Venter,Prudence Ive,Liesl Page-Shipp,Ebrahim Variava,Klaus Reither,Klaus Reither,Nyanda E. Ntinginya,Alexander Pym,Florian von Groote-Bidlingmaier,Mendel Carl M +21 more
TL;DR: A novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant tuberculosis during the first 8 weeks of treatment was investigated, and the combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity.
Journal ArticleDOI
Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay-A Clinical Validation Study
Andrea Rachow,Alimuddin Zumla,Norbert Heinrich,Gabriel Rojas-Ponce,Bariki Mtafya,Klaus Reither,Klaus Reither,Elias N. Ntinginya,Justin O'Grady,Jim F. Huggett,Keertan Dheda,Catharina Boehme,Mark D. Perkins,Elmar Saathoff,Michael Hoelscher +14 more
TL;DR: The Xpert MTB/RIF Assay is a highly sensitive, specific and rapid method for diagnosing TB which has potential to complement the current reference standard of TB diagnostics and increase its overall sensitivity.
Journal ArticleDOI
Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study
Andrea Rachow,Petra Clowes,Petra Clowes,Elmar Saathoff,Bariki Mtafya,Epiphania Michael,Elias N. Ntinginya,Dickens Kowour,Gabriel Rojas-Ponce,Arne Kroidl,Arne Kroidl,Leonard Maboko,Norbert Heinrich,Klaus Reither,Klaus Reither,Klaus Reither,Michael Hoelscher +16 more
TL;DR: Xpert was easy to perform and displayed similar diagnostic accuracy as culture methods in children with suspected tuberculosis in a high tuberculosis/HIV-burden setting, although sensitivity remains suboptimal and access is dependent on local laboratory infrastructure.